Valence8 US’s Climb Bio CLYM Stock Holding History

Valence8 US’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,045	Closed	-$61.3K	–	63
2024 Q3	$61.3K	Buy	+12,045	New	+$85.2K	0.03%	57

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Valence8 US's CLYM Position: Q4 2024 in Review

Valence8 US sold out of Climb Bio (CLYM) in Q4 2024, closing a stake of 12,045 shares — an estimated $61.3K sold.

Valence8 US first reported a position in CLYM in Q3 2024 and held it in 1 quarter. The position peaked at $61.3K in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q4 2024.

Valence8 US reported no remaining Climb Bio position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 12,045 Climb Bio shares in Q4 2024, an estimated $61.3K.
Valence8 US first reported a position in Climb Bio in Q3 2024 and held it in 1 quarter.
Valence8 US's Climb Bio position peaked at $61.3K in Q3 2024.
80 funds tracked by Wall St. Rank held Climb Bio as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.